Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 13Neoplasms 12Glioma 12Glioblastoma 11Prostatic Neoplasms 10Colorectal Neoplasms 10Brain Neoplasms 10Pancreatic Neoplasms 9Neoplasm Metastasis 9Melanoma 8Lymphoma, B-Cell 8Lymphoma 8Recurrence 7Multiple Myeloma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Skin Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Solid Tumor 3Pituitary Neoplasms 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Lung Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

sugemalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pleural Effusion, Malignant × 90 days × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡